The role of IL-12 in the induction of an immune response to a tumor/self peptide: Prevention and reversion of anergy

Journal of Chemotherapy

Volumn 10, Issue 2, 1998, Pages 157-159

  Belladonna, M L ^a,c   Grohmann, U ^a   Bianchi, R ^a   Ayroldi, E ^a   Surace, D ^b   Puccetti, P ^a   Fioretti, M C ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c Dip Medicina Sperimentale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNTHETIC PEPTIDE; TUMOR REJECTION ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; CONFERENCE PAPER; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; IMMUNE RESPONSE; MOUSE; NONHUMAN;

EID: 0031920752     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.2.157     Document Type: Conference Paper

References (5)

1. Lethé B, Van den Eynde B, Van Pel A, Corradin G, Boon T. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 1992; 22; 2283-8.
2. + cell activation to a major mastocytoma rejection antigen. P815AB: requirement for turn or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 1995; 25; 2797-2802.
3. Bianchi R, Grohmann U, Belladonna ML, et al. IL-12 is both required and sufficient for initiating T-cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol 1996; 157; 1589-1597.
4. Uyttenhove C, Maryansky J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157; 1040-1052.
5. Grohmann U, Bianchi R, Ayroldi E, et al. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 1997; 158; 3593-3602.